Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Don Pueblo who wrote (63194)	9/25/1999 9:08:00 AM
From: kendall harmon	Respond to of 120523

ARNX--more on the Conference at which they are presenting Sunday: <<A great way for biotech investors to make potentially quick gains is to watch the scientific conference schedule and figure out which companies will be spotlighted. This is a great forum for biotechs to strut their stuff in front of analysts and institutions that may not have previously known anything about the company. The bigger the conference is, the better the national exposure. Stocks sometimes move higher with positive data on products, and occasionally tank on better news from a competitor, even if the company presents positive results itself. The Interscience Conference on Antimicrobial Agents and Chemotherapy is a conference that focuses on infectious diseases, and is scheduled Sept. 26-29 in San Francisco. ICAAC has become one of the major scientific forums for presentations on pipeline products for HIV and AIDS. This year's conference will include data from products that treat diseases such as influenza (the flu) and the common cold. The best forum to display positive results is the "late-breaking" sessions. The conference room during these sessions is packed liked a can of sardines, with mutual fund managers and physicians standing side by side awaiting a company's announcement that it has a cure for AIDS. It's been said that more than five times as many studies are submitted as are eventually accepted. How do you find out about the late-breaker sessions? Call companies directly, fastidiously check out the conference Web site and read analyst reports - there are numerous ways. >> Source: ragingbull.com <<Anthony H. Williams, M.D., Vice President Medical Affairs, Aronex Pharmaceuticals, will present data from the completed Phase III clinical trial, which evaluated NYOTRAN in 538 patients with presumed fungal infections who had failed 72 hours of previous antibacterial therapy. The data will be presented on Sunday, September 26, 1999, at 12:24 p.m. in Late Breaker Session Number 29 in Room 103/104. Five separate posters or presentations on NYOTRAN will be presented during the ICAAC conference from September 26-29, 1999. A schedule of the presentations and posters is listed below, and copies of the abstracts may be obtained from the ICAAC website at www.asmusa.org, or by contacting Aronex Pharmaceuticals' Corporate Communications Department.>>

To: Don Pueblo who wrote (63194)	9/26/1999 1:38:00 AM
From: Scrumpy	Respond to of 120523

I agree. If I were to embark on a more permanent day-trading career, I'd run myself through some hard-core "scalp" training at EdgeTrade or Attain. They won't let you trade until you've squeezed out the emotion and harden into a trading machine after three weeks and $3-5G of practice. Ultimately though, the vicissitudes of the market are just incredible. I've had the most solid trends under me turn ugly in a tick...and only after repetition does one learn to cut (and forget about) the small losses and keep on moving. You are right about knowing (and adhering to) entry and exit points. The minute I turn greedy, then I know it's time to take my profit or risk getting slammed...but never with my entire roll <gg>. HT, Scrumpy